Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease Evidence-based Recommendations

An evidence-based guideline for the treatment of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) was created in 2023 by a panel ofmultidisciplinary experts (1). Systematic literature reviews were performed for the following therapies: cyclophosphamide, mycophenolate, rituximab, tocilizumab, nintedanib, combination of nintedanib plus mycophenolate, pirfenidone, and combination of pirfenidone plusmycophenolate. The purpose of this article is to provide a concise summary for clinicians with key points about the treatment recommendations fromthe guideline to facilitate their implementation within the context of patient preferences, and it is not intended to represent a standard of care for patients with SSc-ILD. The implications of the guideline recommendations for clinicians, patients, and policymakers are noted in Table 1.